Absci Corporation is a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design. Absci Corporation is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $2.80M |
| Net Income (Most Recent Fiscal Year) | $-115.18M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 950.28 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.46 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -8457.10% |
| Net Margin (Trailing 12 Months) | -8451.31% |
| Return on Equity (Trailing 12 Months) | -61.60% |
| Return on Assets (Trailing 12 Months) | -55.30% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.64 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.64 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.27 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.17 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.88 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.79 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 172.75M |
| Free Float | 154.57M |
| Market Capitalization | $1.41B |
| Average Volume (Last 20 Days) | 4.57M |
| Beta (Past 60 Months) | 2.22 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.52% |
| Percentage Held By Institutions (Latest 13F Reports) | 52.05% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |